Skip to main content
ANTX logo

ANTX · AN2 Therapeutics, Inc.

Track ANTX — free
$5.89 -0.06 (-1.01%) At close · Sep 4
Market Cap
$222.64M
Shares
37.74M

ANTX metrics

49 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.89
Market cap
$222.64M

Price action

19 metrics
Price change (1W)
+5.6%
Price change (30D)
-3.1%
Price change (3M)
+54.2%
Price change (6M)
+106.7%
Price change (YTD)
+416.7%
Price change (1Y)
+367.5%
Trailing year
Price change (5Y)
52-week high
$6.28
52-week low
$1.03
Change from 52-week high
-6.2%
Change from 52-week low
+471.8%
Annualized volatility
131.2%
Beta
0.6
RSI (14D)
56.8
Price vs SMA 50
+11.0%
Price vs SMA 200
+74.2%
Avg volume (3M)
284,521
Relative volume
0.3
Average dollar volume
$1.48M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
37.74M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
P / book
2.9
reciprocal yield 34.1%
FCF yield
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-16.3%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2026-05-19

Profitability

9 metrics
Gross margin
Operating margin
Trailing 12 months
Net margin
Gross profit (TTM)
Operating profit (TTM)
−$38.81M
Net income (TTM)
−$36.28M
Trailing 12 months
Diluted EPS (TTM)
$-1.07
FCF margin
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$-17.36

Growth

11 metrics
Revenue growth YoY
Year over year
Net income growth YoY
Revenue (TTM)
Trailing 12 months
EPS growth YoY
Shares change YoY
+48.4%
Year over year · more shares
Revenue CAGR (3Y)
Revenue CAGR (5Y)
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-47.8%
Return on assets
-44.4%
Debt / equity
Current ratio
14.3
EBITDA (TTM)
Free cash flow (TTM)
Quick ratio
14.3
Interest coverage
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
$44.32M
Latest balance sheet
Cash & equivalents
$44.32M
Total assets
$81.68M
Total debt

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$30.68M
Capital expenditures (TTM)
R&D (TTM)
$26.64M
SG&A (TTM)
Stock compensation (TTM)
$4.63M
R&D / revenue
Stock compensation / revenue

Ownership (13F)

3 metrics
13F filers
66
13F filer change QoQ
+14
Institutional ownership
65.1%

Short interest

3 metrics
Short interest
5.9%
Latest settlement · 10.1 days to cover
Days to cover
10.1d
Short-squeeze score
79 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$227,407
Insider-sentiment score
53 / 100

Risk flags

1 metrics
Going concern
Key facts CIK 1880438 CUSIP 037326105 13F (30d) 58 filings 58 filers Visit website Investor relations